Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

REM 422

Next Previous
Drug Profile

REM 422

Alternative Names: REM-422

Latest Information Update: 01 Apr 2026

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Remix Therapeutics
  • Class Antineoplastics; Small molecules
  • Mechanism of Action Proto-oncogene protein c-myb expression inhibitors; RNA degraders
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Adenoid cystic carcinoma; Acute myeloid leukaemia
  • New Molecular Entity Yes

Highest Development Phases

  • Phase I/II Adenoid cystic carcinoma
  • Phase I Acute myeloid leukaemia; Myelodysplastic syndromes

Most Recent Events

  • 19 Mar 2026 REM 422 receives Fast Track designation for Adenoid cystic carcinoma [PO,Capsule] (Late-stage disease, Metastatic disease, Recurrent) in USA
  • 24 Oct 2025 Pharmacokinetics, efficacy and adverse events data from a phase I trial in Adenoid cystic carcinoma released by Remix Therapeutics
  • 22 Oct 2025 Pharmacokinetics, pharmacodynamics, efficacy and adverse events data from a phase I trial in Adenoid cystic carcinoma presented at the International Conference on Molecular Targets and Cancer Therapeutics 2025 (AACR-NCI-EORTC-2025)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top